zolmitriptan Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
serotonin (5-HT1) receptor agonists, sumatriptan derivatives 2869 139264-17-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zolmitriptan
  • zipton
  • zominat
  • zomigoro
  • 311C90
an antimigraine compound; a serotonin (5HT)-1D receptor agonist
  • Molecular weight: 287.36
  • Formula: C16H21N3O2
  • CLOGP: 1.29
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 57.36
  • ALOGS: -3.18
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.50 mg N
2.50 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 8 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.50 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 45 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
fu (Fraction unbound in plasma) 0.75 % Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution) 1.80 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 6.70 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.60 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 25, 1997 FDA IPR

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Migraine 117.83 33.79 32 464 10621 2346968
Headache 83.50 33.79 42 454 80137 2277452
Drug hypersensitivity 68.35 33.79 31 465 46612 2310977
Medication overuse headache 67.60 33.79 9 487 54 2357535
Drug interaction 54.32 33.79 23 473 29140 2328449
Drug dependence 52.15 33.79 13 483 3032 2354557
Nausea 47.62 33.79 33 463 112156 2245433
Vitreous detachment 44.69 33.79 8 488 376 2357213
Colitis ischaemic 43.65 33.79 10 486 1627 2355962
Cerebrovascular accident 41.13 33.79 17 479 20169 2337420
Exposure during pregnancy 40.69 33.79 18 478 25201 2332388
Blood thyroid stimulating hormone normal 38.31 33.79 5 491 25 2357564
Drug abuse 38.23 33.79 14 482 12012 2345577
Nephrolithiasis 37.92 33.79 11 485 4532 2353057
Chest discomfort 35.59 33.79 14 482 14581 2343008
Dyspnoea 35.23 33.79 24 472 78709 2278880
Drug ineffective 34.10 33.79 26 470 101598 2255991

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event

Pharmacologic Action:

SourceCodeDescription
ATC N02CC03 NERVOUS SYSTEM
ANALGESICS
ANTIMIGRAINE PREPARATIONS
Selective serotonin (5HT1) agonists
CHEBI has role CHEBI:35941 serotonergic agonist
CHEBI has role CHEBI:50514 vasoconstrictor agent
CHEBI has role CHEBI:35472 anti-inflammatory drug
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
FDA MoA N0000175763 Serotonin 1b Receptor Agonists
FDA MoA N0000175764 Serotonin 1d Receptor Agonists
FDA EPC N0000175765 Serotonin-1b and Serotonin-1d Receptor Agonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Hemiplegic migraine contraindication 59292006
Cerebral arteriosclerosis contraindication 65312002
Wolff-Parkinson-White pattern contraindication 74390002 DOID:384
Vascular insufficiency of intestine contraindication 82196007
Prinzmetal angina contraindication 87343002
Kidney disease contraindication 90708001 DOID:557
Angina pectoris contraindication 194828000
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Transient ischemic attack contraindication 266257000 DOID:224
Raynaud's phenomenon contraindication 266261006
Cerebral ischemia contraindication 287731003
Cardiovascular event risk contraindication 395112001
Peripheral vascular disease contraindication 400047006
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Hypertensive urgency contraindication 443482000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.47 acidic
pKa2 8.28 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.90 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 7.70 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1F GPCR Ki 7.45 WOMBAT-PK
5-hydroxytryptamine receptor 1E GPCR Ki 7.70 WOMBAT-PK
5-hydroxytryptamine receptor 1A GPCR Ki 6.60 WOMBAT-PK
Adrenergic receptor alpha-2 GPCR Kd 8.15 CHEMBL
D(2) dopamine receptor GPCR Kd 10.40 CHEMBL
D(1A) dopamine receptor GPCR Kd 9.52 CHEMBL

External reference:

IDSource
4021094 VUID
N0000148550 NUI
C0528166 UMLSCUI
D00415 KEGG_DRUG
2FS66TH3YW UNII
7408 INN_ID
108406003 SNOMEDCT_US
4021094 VANDF
006460 NDDF
135775 RXNORM
d04253 MMSL
52759 MMSL
5712 MMSL
363582006 SNOMEDCT_US
CHEBI:10124 CHEBI
CHEMBL1185 ChEMBL_ID
DB00315 DRUGBANK_ID
60857 PUBCHEM_CID
60 IUPHAR_LIGAND_ID
C089750 MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 0115-0671 TABLET 2.50 mg ORAL NDA 17 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 0115-0672 TABLET 5 mg ORAL NDA 17 sections
Zolmitriptan Orally Disintegrating HUMAN PRESCRIPTION DRUG LABEL 1 0115-0691 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL NDA 17 sections
Zolmitriptan Orally Disintegrating HUMAN PRESCRIPTION DRUG LABEL 1 0115-0692 TABLET, ORALLY DISINTEGRATING 5 mg ORAL NDA 17 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 21695-955 SPRAY, METERED 5 mg NASAL NDA 19 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 27241-021 TABLET 2.50 mg ORAL ANDA 17 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 27241-022 TABLET 5 mg ORAL ANDA 17 sections
ZOLMITRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 31722-458 TABLET, FILM COATED 2.50 mg ORAL ANDA 18 sections
ZOLMITRIPTAN HUMAN PRESCRIPTION DRUG LABEL 1 31722-459 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 46708-181 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 18 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 46708-182 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 18 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 46708-462 TABLET, FILM COATED 2.50 mg ORAL ANDA 17 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 46708-463 TABLET, FILM COATED 5 mg ORAL ANDA 17 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 50742-625 TABLET, FILM COATED 2.50 mg ORAL ANDA 17 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 50742-626 TABLET, FILM COATED 5 mg ORAL ANDA 17 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 59746-432 TABLET, FILM COATED 2.50 mg ORAL ANDA 17 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 59746-433 TABLET, FILM COATED 5 mg ORAL ANDA 17 sections
Zolmitriptan OD HUMAN PRESCRIPTION DRUG LABEL 1 59746-461 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 18 sections
Zolmitriptan OD HUMAN PRESCRIPTION DRUG LABEL 1 59746-462 TABLET, ORALLY DISINTEGRATING 5 mg ORAL ANDA 18 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 63548-0101 TABLET, FILM COATED 2.50 mg ORAL ANDA 17 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 63548-0102 TABLET, FILM COATED 5 mg ORAL ANDA 17 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 64896-671 TABLET 2.50 mg ORAL NDA 17 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 64896-672 TABLET 5 mg ORAL NDA 17 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 64896-681 SPRAY, METERED 5 mg NASAL NDA 18 sections
ZOMIG HUMAN PRESCRIPTION DRUG LABEL 1 64896-682 SPRAY, METERED 2.50 mg NASAL NDA 18 sections
ZOMIG ZMT HUMAN PRESCRIPTION DRUG LABEL 1 64896-691 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL NDA 17 sections
ZOMIG ZMT HUMAN PRESCRIPTION DRUG LABEL 1 64896-692 TABLET, ORALLY DISINTEGRATING 5 mg ORAL NDA 17 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 64980-203 TABLET, FILM COATED 2.50 mg ORAL ANDA 17 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 64980-204 TABLET, FILM COATED 5 mg ORAL ANDA 17 sections
Zolmitriptan HUMAN PRESCRIPTION DRUG LABEL 1 64980-256 TABLET, ORALLY DISINTEGRATING 2.50 mg ORAL ANDA 17 sections